Stocks and Investing
Stocks and Investing
Tue, December 19, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Leland Gershell Maintained (VRDN) at Buy with Increased Target to $36 on, Dec 19th, 2023
Leland Gershell of Oppenheimer, Maintained "Viridian Therapeutics, Inc." (VRDN) at Buy with Increased Target from $35 to $36 on, Dec 19th, 2023.
Leland has made no other calls on VRDN in the last 4 months.
There are 6 other peers that have a rating on VRDN. Out of the 6 peers that are also analyzing VRDN, 0 agree with Leland's Rating of Hold.
These are the ratings of the 6 analyists that currently disagree with Leland
- Douglas Tsao of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $37 on, Monday, December 18th, 2023
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $35 on, Thursday, December 14th, 2023
- Laura Chico of "Wedbush" Reiterated at Buy and Held Target at $37 on, Monday, December 4th, 2023
- Jason Butler of "JMP Securities" Maintained at Buy with Decreased Target to $38 on, Tuesday, November 14th, 2023
- Serge Belanger of "Needham" Maintained at Strong Buy with Decreased Target to $30 on, Monday, October 30th, 2023
- Alex Thompson of "Stifel" Reiterated at Strong Buy and Held Target at $40 on, Wednesday, September 13th, 2023
Contributing Sources